IBCN annual meeting included a bladder cancer session, featuring a presentation by Dr. Amanda Myers discussing the ...

In vivo, using the subcutaneous MB49 bladder cancer model, HSV5-15 virus expressing both the cytokine and TLR agonist ...

IBCN annual meeting included a keynote lecture by Dr. Niko Beerenwinkel discussing inferring tumor evolution from single-cell data. Although the majority of work has been done in other cancers (ie.

IBCN annual meeting included a session on novel therapies and outcome measures in clinical trials, featuring a presentation by Dr. Gautier Marcq discussing the benefit of whole-pelvis radiation for ...

(UroToday.com) The 2024 IBCN annual meeting included a session on molecular subtyping in the 2024, featuring a presentation by Dr. Saum Ghodoussipour discussing the LUMBER-NAC trial in progress. A ...

Undetectable pre-cystectomy ctDNA predicts better pathological outcomes post-radical cystectomy Patients with undetectable pre-cystectomy status demonstrated recurrence-free survival, regardless of ...

(UroToday.com) The 2024 European Society for Medical Oncology (ESMO) Annual Congress held in Barcelona, Spain between September 13 th and 16 th, 2024 was host to a session focusing on rare ...

(UroToday.com) The 2024 ESMO annual meeting included a session on prostate cancer, featuring a presentation by Dr. Niven Mehra discussing nivolumab 3mg/kg and ipilimumab 1mg/kg in molecularly selected ...

How renal mass biopsy (RMB) impacts patient management with T1 renal masses (T1RM) is unclear. We explore the association between RMB and utilization of active surveillance (AS), nephron-sparing ...

Testicular cancer survivors (TCS) exposed to chemotherapy have an increased expression of CDKN2A/p16INK4a and a lymphocyte phenotype associated with immunosenescence. We seek to define whether the ...

The high costs of cancer care can cause significant harm to patients and society. Prostate cancer, the leading nonskin malignancy in men, is responsible for the second-highest out-of-pocket (OOP) ...

Both direct and indirect costs contribute to financial toxicity in prostate cancer. Indirect costs are difficult to assess and quantify and therefore remain understudied. We sought to describe the ...